Key points from article :
The artificial intelligence-powered drug discovery company insitro secured $400 million.
“For insitro, 2020 was a year of incredible growth and progress toward our founding vision of bringing the predictive powers of machine learning to drug discovery,” - Daphne Koller, CEO and founder of insitro.
"A big step forward towards moving from targets to medicines through the acquisition of Haystack Sciences," - Koller.
Announced a five-year project with Bristol Myers Squibb to bring machine learning programs to ALS and dementia research.
Insitro will build induced pluripotent stem cell models of the neurodegenerative diseases.
Uses machine learning and genomics research, before digitally generating new drug candidates.
“This series C financing, alongside our series B in mid-2020 will expand our work towards bringing transformative medicines to patients faster and with fewer failures," - Koller.
